NASDAQ: TECH · Life Sciences · 4 alerts · CIK 842023
Share price
$72.79Close, Nov 16
Market cap
$11.4B
Shares outstanding
157.06MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BIO-TECHNE Corp filings on SEC EDGAR ↗
Bio-Techne reported net sales of $299.7 million for the quarter ended September 30, 2026, a 4.6% increase over the prior year. However, net earnings decreased to $28.3 million from $38.2 million, primarily driven by higher selling, general, and administrative expenses and a shift in other income/expense.
Bio-Techne Corporation declared a quarterly cash dividend of $0.08 per share for the quarter ended September 30, 2026. The dividend is payable on November 23, 2026, to shareholders of record as of November 13, 2026, contingent upon the company's pending acquisition by Merck KGaA not closing before the record date.
BIO-TECHNE M&A Deal with Merck KGaA, Darmstadt, Germany
Bio-Techne shareholders voted to approve the company's acquisition by Merck KGaA, Darmstadt, Germany, at a special meeting held on September 23, 2026. The transaction has also cleared the HSR Act antitrust waiting period and is expected to close by late 2026 or early 2027. Bio-Techne will become a wholly-owned subsidiary of Merck KGaA upon completion of the merger.
BIO-TECHNE M&A Deal with Merck KGaA, Darmstadt, Germany
Bio-Techne Corporation provided a status update on its pending merger with Merck KGaA, Darmstadt, Germany, specifically addressing shareholder litigation and demand letters alleging disclosure deficiencies in the proxy statement. To avoid potential delays to the merger and the scheduled September 23, 2026 shareholder vote, the company has voluntarily issued supplemental disclosures while maintaining that the legal claims are without merit.